Tradestie Institutional Equity Comparison Engine

CVM vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
CVM 23.0x vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin 0.0% vs -485.4% ยท YoY -62.7% vs +408.6%
Momentum & Technical Winner SRZN
1Y -73.0% vs +130.6% ยท 52W Pos 15% vs 69%
Options & Structure Winner SRZN
BREAKDOWN (N/A IV) vs CONSOLIDATION (5th %ile IV)
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.91
+14.76% 1D
Market Cap $22.5M
1M Return +15.45%
1Y Return -72.98%
Forward P/E 23.0x
Unified AI Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
1M Return +25.57%
1Y Return +130.62%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CVM -72.98% SRZN +130.62% Spread: +201.84 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CVM Revenue SRZN Revenue CVM Op. Margin SRZN Op. Margin Margin Edge
FY2011 $0M N/A -1881.0% N/A CVM
FY2012 $0M N/A -6772.3% N/A CVM
FY2013 $0M N/A -12450.1% N/A CVM
FY2014 $0M N/A -9721.4% N/A CVM
FY2022 N/A $10M N/A -354.7% SRZN
FY2024 N/A $10M N/A -239.7% SRZN
FY2025 N/A $0M N/A -1210.6% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CVM (4) vs SRZN (5)
Institutional Metric CVM SRZN Criterion Row Winner
Market Capitalization Scale $22.5M $602.5M Larger Scale SRZN
Trailing P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Revenue Growth (YoY) Growth -62.7% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability 0.0% -485.4% Higher Margin CVM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -252.5% -62.8% Higher ROE SRZN
52-Week Range Position Momentum 15% ($1โ€“$8) 69% ($12โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 0.45ฮฒ ยท 139% Vol 1.28ฮฒ ยท 66% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 33.2 / 100 (SELL) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CVM vs SRZN Buy Guide
CVM BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CVM nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.